double-blind

(redirected from double-blinded)
Also found in: Dictionary.
Related to double-blinded: single blind, double-blind experiment, single blind experiment, Triple blind, single blind study

double-blind

, double-blinded (dub'el-blind')
Pert. to a method, study, or clinical trial in which neither the subjects nor the investigators know the identities of the subjects nor what treatment or medication, if any, the subjects receive. A double-blind study attempts to eliminate observer and subject bias.
See: blind (2); single-blind
References in periodicals archive ?
In a double-blinded pilot study, involving 20 human subjects over four weeks, OBE101 reduced both calorie and fat intake in the treatment group, resulting in significant weight loss versus placebo.
In a meta-analysis of 10 randomized, double-blinded, placebo-controlled trials of approved Alzheimer's disease drugs, published in 2006(1), treatment with these drugs produced an average ADAS-cog improvement over placebo of 2.
As the first step in its subsequent development plans, Medivation today also announced that in the second quarter of 2006 it initiated a double-blinded extension study which allows patients from the Phase 2 study to continue treatment for up to a total of 12 months in the same treatment group to which they originally were randomized.
In the course of the study, 326 patients who met the 1988 Centers for Disease Control (CDC) criteria for Chronic Fatigue Syndrome (CFS), participated in two randomized, placebo-controlled, double-blinded, multicenter, evaluations of poly I: ploy C12U in the treatment of CFS.
In this regard, we have had a few shareholders ask if the control arm in our monotherapy double-blinded clinical trial described in the second paragraph above was a chemotherapeutic.
conducted a six-week double-blinded study to test the effectiveness of NDC's nutraceutical formulation, which contains a natural occurring plant alkaloid (S-3-(1-methyl-2-pyrrolidinyl)pyridine), as the primary active component.
MS complex has completed a randomized, double-blinded, placebo-controlled, dose escalation clinical trial.
This study remains double-blinded and dosing will continue through the completion of 48 weeks of therapy for enrolled patients.